Liver Fibrosis Due to Nonalcoholic Steatohepatitis
📧 Sign up to get email alerts when something new happens for Liver Fibrosis Due to Nonalcoholic Steatohepatitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH [Phase 2]
Phase 2 trial of simtuzumab for liver fibrosis due to nonalcoholic steatohepatitis (NASH) was terminated.
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) [Phase 2]
Phase 2 trial evaluating safety and efficacy of simtuzumab in adults with advanced liver fibrosis due to NASH; study terminated with posted …